TREATMENT OUTCOMES FOR CHILDREN WITH ANXIETY DISORDERS

焦虑症儿童的治疗结果

• 批准号: 6650210
• 负责人: Moira Ann Rynn
• 金额: $ 16.44万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-08-02 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6650210
• 关键词: anxiety disorders; clinical research; clinical trials; emotions; human subject; human therapy evaluation; mental disorder chemotherapy; middle childhood (6-11); outcomes research; pediatrics; psychopharmacology; sertraline

This application proposes Moira A. Rynn, M.D. for a Mentored Patient-Oriented Research Career Development Award at the University of Pennsylvania. The aims of this program include: 1) to support my development into an independent research scientist; 2) to support and enhance my development as an investigator in anxiety disorders in children and adolescents; 3) to develop my ability to use my clinical experience to design and execute a protocol that will answer a proposed research question; and 4) to provide the groundwork for the preparation of an RO1 grant application based on the research performed during the award period. These aims will be accomplished through a structured four-part plan: 1) to complete a Master's of Science of Clinical Epidemiology, a program of formal academic courses and tutorials to enhance my research skills, under the supervision of Dr. Brian Strom; 2) to obtain research training and mentoring by a senior scientist who will serve as my sponsor (Karl Rickels, M.D.) as well as by a co-sponsor (Edna Foa, Ph.D) and collaborators (Elizabeth Weller, M.D., Irwin Lucki, Ph.D., John March, M.D., M.P.H., Brian Strom, M.D., M.P.H., and Philip C. Kendall, Ph.D., ABPP); 3) to participate in several ongoing psychopharmacological trials for anxiety and depression in both children and adults in the Mood and Anxiety Disorders Section; and 4) to design and execute an original clinical research treatment protocol. Children aged 8 to 12 years and 11 months who meet the diagnosis of generalized anxiety disorder, separation anxiety disorder, or anxiety disorder nos will enter a randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of 50 mg sertraline per day (Pt N = 60). I also will evaluate the moderating effect the presence of parental psychopathology has on the child's level of impairment, onset of disorder and response to medication treatment. Families will be followed for one year to collect for further research.

该申请建议Moira A. Rynn，医学博士，颁发宾夕法尼亚大学的指导性研究职业发展奖。 该计划的目的包括：1）支持我成为独立研究科学家的发展； 2）支持和增强我作为儿童和青少年焦虑症研究者的发展； 3）发展我利用临床经验设计和执行将回答拟议研究问题的协议的能力； 4）为根据奖励期间进行的研究提供基础，以准备RO1赠款申请。这些目标将通过一个结构化的四部分计划来实现：1）在Brian Strom博士的监督下，完成了临床流行病学硕士学位，该计划是一项正式的学术课程和教程的计划，以增强我的研究技能； 2）要获得一位高级科学家的研究培训和指导，他将担任我的赞助商（Karl Rickels，M.D。）以及共同赞助商（Edna Foa，Ph.D）和合作者（Elizabeth Weller，M.D。，M.D.，M.D.，Irwin Lucki，Ph.D。博士，ABPP）; 3）参加情绪和焦虑症部分的几项正在进行的心理药理学试验，以解决儿童和成人的焦虑和抑郁症； 4）设计和执行原始的临床研究治疗方案。符合普遍焦虑症，分离焦虑症或焦虑症的诊断为8至12岁零11个月的儿童将进入一项随机的，双盲的，安慰剂对照试验，以评估每天50 mg舍曲林的安全性和功效（pt n = 60）。 我还将评估父母心理病理学对儿童障碍水平，疾病发作和对药物治疗的反应水平的调节作用。 将遵循家庭一年来收集进一步的研究。